US equities
|
SPCX
$167.60
▲+5.44%
NVDA
$237.23
▲+1.40%
MU
$1,065.23
▼-0.90%
TSLA
$377.93
▲+1.98%
MSFT
$525.41
▲+1.52%
SNDK
$1,708.73
▼-0.65%
INTC
$116.97
▼-1.98%
META
$743.94
▲+2.18%
SPCX
$167.60
▲+5.44%
NVDA
$237.23
▲+1.40%
MU
$1,065.23
▼-0.90%
TSLA
$377.93
▲+1.98%
MSFT
$525.41
▲+1.52%
SNDK
$1,708.73
▼-0.65%
INTC
$116.97
▼-1.98%
META
$743.94
▲+2.18%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Noveris Health Sciences
(OP:
MYCOF
)
0.7300
UNCHANGED
Last Price
Updated: 12:48 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Noveris Health Sciences
< Previous
1
2
3
4
5
6
7
Next >
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans
February 08, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program
February 08, 2022
Via
Investor Brand Network
Topics
Supply Chain
Mydecine Innovations Group develops novel compounds for treating mental health
February 07, 2022
Via
AB Newswire
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale
February 03, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses
February 02, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation
February 01, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market
January 31, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices
January 24, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans
January 24, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to Launch Specialized Psychedelic Program in Canada
January 24, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies
January 18, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy
January 13, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast
January 11, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program
January 10, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program
January 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’
January 06, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation
January 05, 2022
Via
Investor Brand Network
Topics
Death
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
↗
January 02, 2022
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the...
Via
Talk Markets
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds
December 30, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
↗
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform
December 22, 2021
Via
Investor Brand Network
The Year In Review For Psychedelic Drug Stocks: 2021
↗
December 21, 2021
2021 was two different
Via
Talk Markets
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine
December 20, 2021
Via
Investor Brand Network
Topics
Cannabis
Intellectual Property
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment
December 20, 2021
Via
Investor Brand Network
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
↗
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
Mind Medicine to Study Effect of Time on LSD Microdosing
↗
December 17, 2021
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a...
Via
Benzinga
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing
December 17, 2021
Via
Investor Brand Network
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies
December 16, 2021
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
↗
December 12, 2021
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...
Via
Talk Markets
Topics
Cannabis
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin
December 10, 2021
Via
Investor Brand Network
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
